Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
0.9
Journals
Reports
Sections
Clinical Research in Oncology
share announcement

Clinical Research in Oncology

A topical collection in Reports (ISSN 2571-841X).

Viewed by 4455

Editor

Prof. Dr. Syed A. A. Rizvi

E-Mail Website
Collection Editor
School of Pharmacy, Hampton University, 121 William R. Harvey Way, Hampton, VA 23668, USA
Interests: medical chemistry; drug development; formulations; chemical analysis; bioactivity; natural products; chirality; nanotechnology; material sciences
Special Issues, Collections and Topics in MDPI journals

Topical Collection Information

Dear Colleagues,

The abnormal proliferation of cells in the body, leading to the development of either benign or malignant cancer, can happen in any type of cell. Thus, many types of cancers require unique differential diagnosis and custom treatment options. Despite momentous advances in biological and chemical sciences, early diagnosis and the safe and complete eradication of cancer from the human body is still a major challenge. According to the World Health Organization [1], “Cancer is the second leading cause of death globally, and is responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer.”

In this Topical Collection, we describe unusual clinical cases of cancer pathologies and outline cases of challenging diagnosis and treatment. Studies describing the utilization of new compounds, both synthetic and isolated, that show promising anticancer activities and/or superior diagnosis are also welcome.

1. World Health Organization. Available online: https://www.who.int/news-room/fact-sheets/detail/cancer (accessed on 24 July 2019).

Prof. Dr. Syed A. A. Rizvi
Collection Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Reports is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • unusual presentation
  • challenging differential diagnoses
  • new cancer treatments
  • in vitro models
  • in vivo models

Published Papers (2 papers)

Download All Papers

2023

Jump to: 2022

6 pages, 2176 KiB  
Case Report
Favorable Outcome and Safety of Neoadjuvant Trastuzumab Emtansine (T-DM1) in a HER2-Positive Early Breast Cancer Patient with Severe Renal Disease on Hemodialysis Ineligible for Conventional Chemotherapy: A Case Report
by Suman Kalyan Natarajan, Joice Crystal Danansezhian, Vipulkumar Thummar and Priya Mehta
Reports 2023, 6(1), 13; https://doi.org/10.3390/reports6010013 - 02 Mar 2023
Viewed by 1586
Abstract
Breast cancer is the leading cause of cancer-related death among women worldwide. It is the most common malignancy in middle-age and elderly women already suffering from other comorbidities, such as chronic kidney disease (CKD). Being a heterogeneous disease, it has variable subtype-specific outcomes [...] Read more.
Breast cancer is the leading cause of cancer-related death among women worldwide. It is the most common malignancy in middle-age and elderly women already suffering from other comorbidities, such as chronic kidney disease (CKD). Being a heterogeneous disease, it has variable subtype-specific outcomes and responses towards treatment. Patients with human epidermal growth factor receptor 2 (HER2) overexpression are treated with anti-HER2-targeted drugs. With the advent of newer drugs, the usage of HER2 blockade and chemotherapy in the neoadjuvant treatment of HER2-positive early breast cancer management helps to increase the probability of achieving pathological complete response. We herein present a case of a patient with breast cancer with long-standing CKD and on maintenance hemodialysis where treatment with conventional chemotherapy regimens was a concern and managed with an antibody–drug conjugate (ADC), namely T-DM1, in a neoadjuvant setting. The patient showed a favorable outcome, and the tolerance of T-DM1 in this patient was predictable. This is a first-of-its-kind case report, where T-DM1 was used in a neoadjuvant setting for a patient on simultaneous hemodialysis. Full article
►▼ Show Figures

Figure 1

2022

Jump to: 2023

8 pages, 5035 KiB  
Case Report
When Histological Tumor Type Diagnosed on Core Biopsy Changes Its Face after Surgery: Report of a Deceptive Case of Breast Carcinoma
by Antonio d’Amati, Marta Mariano, Francesca Addante, Giovanna Giliberti, Giovanni Tomasicchio and Mauro Giuseppe Mastropasqua
Reports 2022, 5(4), 38; https://doi.org/10.3390/reports5040038 - 22 Sep 2022
Viewed by 2201
Abstract
The presence of stromal osteoclast-like giant cells is a distinctive feature of some rare breast tumors, accounting for less than 1% of all breast cancer cases. Although the presence of stromal osteoclast-like giant cells may be encountered in different breast tumors, some authors [...] Read more.
The presence of stromal osteoclast-like giant cells is a distinctive feature of some rare breast tumors, accounting for less than 1% of all breast cancer cases. Although the presence of stromal osteoclast-like giant cells may be encountered in different breast tumors, some authors still describe them as a specific tumor type. Usually, a histological diagnosis of breast carcinoma is made by a pathologist through a biopsy, which is then confirmed through a surgical specimen: it is rare for the two to differ, particularly when there are pathognomonic morphological markers, such as osteoclast-like giant cells. Herein, we report a case of a 45-year-old pre-menopausal woman, who was found to have a single solid mass in her right breast on screening mammogram. She underwent a core biopsy, which showed a malignant epithelial lesion arranged in tubules, glands, and papillae, intermingled with numerous stromal osteoclast-like giant cells. Therefore, a diagnosis of breast cancer with osteoclast-like giant cells was rendered. Curiously, these cells were no longer detectable in the surgical specimen. Full article
►▼ Show Figures

Figure 1

Back to TopTop